Form 4: Sutro Biopharma CSO Granted Stock Options

Sutro Biopharma's Chief Scientific Officer, Hans-Peter Gerber, was granted 7,925 stock options with a $10.38 exercise price, vesting monthly over four years.

Summary

• Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, Inc. (STRO), was granted 7,925 stock options.
• The options have an exercise price of $10.38 per share.
• The grant date for these options was December 23, 2025.
• The options will vest monthly, with 1/48th of the total award vesting each month, contingent on Mr. Gerber's continued service to the company.
• The first tranche of options is scheduled to vest on January 23, 2026.
• The options have an expiration date of December 23, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive sign for executive retention and alignment of interests with shareholders, reflecting standard compensation practices.

Positives

• The grant of stock options aligns the Chief Scientific Officer's interests with long-term shareholder value.
• The vesting schedule incentivizes continued service and performance from a key executive.

Negatives

• Potential for minor dilution for existing shareholders if options are exercised in the future, though this is a standard compensation practice.

Future Outlook

The stock options vest monthly over 48 months, with the first vesting on January 23, 2026, and an expiration date of December 23, 2035, indicating a long-term incentive for the Chief Scientific Officer's continued service and contribution to the company's future performance.

Industry Context

This is a routine executive compensation event common across the biotechnology and pharmaceutical industries, designed to retain key talent and align executive incentives with long-term company performance.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a standard practice in the biotechnology industry for executive compensation, comparable to similar grants at peer companies like Amgen or Gilead Sciences, aiming to incentivize long-term performance and retention.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also benefits from incentivized executive performance.
• Employees: Reflects standard executive compensation practices, potentially setting a precedent or benchmark for other senior roles.
• Management: Hans-Peter Gerber's compensation package is enhanced, aligning his financial interests with the company's long-term success.

Next Steps

• Monthly vesting of 1/48th of the total option award, commencing January 23, 2026.
• Continued service of Hans-Peter Gerber to Sutro Biopharma, Inc. for vesting to occur.

Key Dates

Keywords

Sutro Biopharma, STRO, Stock Options, Insider Transaction, Executive Compensation, Hans-Peter Gerber, Chief Scientific Officer, Form 4, Equity Grant